sulbactam (unasyn) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics. Sulbactam in combination with semisynthetic antibiotic ampicillin sodium is indicated for the treatment of infections due to susceptible strains of the designated microorganisms: Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli etc; Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. Pneumoniae) tec; Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Combination drugs

( procaine benzylpenicillin (novocaine), sulbactam (unasyn) - other name: ampicillin and sulbactam )
|
( sulbactam (unasyn), durlobactam (Xacduro) - other name: sulbactam-durlobactam (sul-dur) )

Alternative names

(2s,5r)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide | cp-45899 | cp-458992 | cp-45899-2 | penicillanic acid 1,1-dioxide | penicillanic acid dioxide | penicillanic acid sulfone | sulbactam | sulbactam benzathine | sulbactam pivoxil | sulbactam pivoxyl | sulbactam sodium | sultamicillin | unasyn

Organizations (89)

Research & Development (71)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (49)

Approved Indications (6)


 

Bacteroides Infections (approved 1988)

Haemophilus influenzae (approved 1988)

Moraxella catarrhalis (approved 1988)

Peptostreptococcus (approved 1988)

Staphylococcus aureus (approved 1988)

Staphylococcus epidermidis (approved 1988)

Experimental Indications - Clinical Trial Phases 1-4 (43)


 

Abdominal Abscess (Phase 4)

Acinetobacter baumannii (Phase 3)

Acinetobacter Infections (Phase 4)

Appendicitis (Phase 4)

Bacteremia (Phase 3)

Bacterial Infections (Phase 4)

Breast Neoplasms (Phase 4)

Cesarean Section (Phase 3)

Cholecystitis (Phase 4)

Cholecystitis, Acute (Phase 4)

Cholelithiasis (Phase 4)

Chorioamnionitis (Phase 2/Phase 3)

Cleft Palate (Phase 2)

Colitis, Ulcerative (Phase 2)

Communicable Diseases (Phase 4)

Critical Illness (Phase 4)

Drugs, Investigational (Phase 4)

Esophageal Achalasia (Phase 3)

Feeding and Eating Disorders (Phase 4)

Fractures, Open (Phase 4)

Gonorrhea (Phase 4)

Healthcare-Associated Pneumonia (Phase 3)

Healthy Volunteers (Phase 1)

Hemodialysis, Home (Phase 3)

HIV Infections (Phase 1/Phase 2)

Infections (Phase 4)

Intraabdominal Infections (Phase 4)

Jaw Fractures (Phase 1)

Lung Abscess (Phase 3)

Peritonitis (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Aspiration (Phase 3)

Pneumonia, Bacterial (Phase 3)

Pneumonia, Ventilator-Associated (Phase 4)

Premature Birth (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pyelonephritis (Phase 3)

Respiratory Tract Infections (Phase 4)

Skin Diseases, Bacterial (Phase 4)

Stomach Diseases (Phase 4)

Surgical Wound Infection (Phase 4)

Urinary Tract Infections (Phase 4)

Wound Infection (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial Organizations: 71

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue